4basebio Plc - Appointment of Joint Corporate Broker

14 November 2024 4basebio PLC ("4basebio" or the "Company") Appointment of Joint Corporate Broker 14 November 2024 - 4basebio PLC (AIM: 4BB) ("4basebio" or the "Company"), which develops and commercialises the large scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, announces the appointment of RBC Capital Markets as the Company's joint corporate broker, to work alongside Cavendish Capital Markets, with immediate effect. Enquiries 4basebio PLC +44 (0)1223 967 943 Dr. Heikki Lanckriet Joint Corporate Broker +44 (0)20 7653 4000 RBC Capital Markets Rupert Walford / Kathryn Deegan Joint Corporate Broker +44 (0)20 7220 0500 Cavendish Capital Markets Limited Geoff Nash / Nigel Birks Nominated Adviser +44 (0)20 7213 0880 Cairn Financial Advisers LLP Jo Turner / Sandy Jamieson / Ed Downes Notes to Editors About 4basebio 4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company's objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients. This information was brought to you by Cision http://news.cision.com

XLON